Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib

NCT01933945 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01933945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
October 28, 2013
Completion date
November 10, 2017
Enrollment
1,676 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular